Professor Eric Vivier

VivierProfessor Eric Vivier

Centre d’Immunologie de Marseille-Luminy, France

Visit co-ordinated by Nick Huntington and Gabrielle Belz huntington@wehi.EDU.AU 


10 April QIMR Berghofer Medical Research Insitute (Mark Smyth)

22 April 1pm WEHI, Melbourne (Nick Huntington) huntington@wehi.EDU.AU "From NK cells to Innate Lymphoid Cells: function and therapeutic applications"

24 April Malaghan Institute, Wellington, New Zealand (Lindsay Ancelet)

28 April 12pm Centenary Institute (Wolfgang Weninger) "Regulation and clinical manipulation of Innate Lymphoid Cells"


Veterinarian and immunologist by training, Eric Vivier is Director of the Centre d’Immunologie de Marseille-Luminy since 2006. In 1993, after a post-doctoral fellowship at Harvard Medical School, he joined the CIML where he founded the Laboratory “Natural Killer Cells and Innate Immunity” in 1996. This research helped to elucidate the role of NK cells and more broadly to decipher the molecular mechanisms controlling  their activation.

Professor of Immunology at the Faculty of Medicine, Hospital practitioner at the Timone Hospital and the Assistance-Publique Hospitals of Marseille, Eric Vivier opened the way for the development of new therapeutic strategies against cancer and inflammatory diseases. He is one of the scientific founders of the biopharmaceutical company Innate Pharma, a pioneer of global immunotherapy.

Eric Vivier is a member of the Institut Universitaire de France, member of the scientific committee of the LNCC (French National League against Cancer), scientific advisor for the Institute of Hematology-Immunology-Pulmonology (INSERM) and member of the expert committee for the European Research Council (ERC) Starting Grant. Professor Vivier will be spending 6 months Sabbatical period at the WEHI and would visit various branches during this period.


Selected publications in the last 4 years

Vivier E., Ugolini, S. Poster on NK cells: receptors and functions, Nature Reviews Immunology, 2010, 10: 12

Vivier E., Raulet D.H., Moretta A., Caligiuri M.A., Zitvogel L., Lanier L.L., Yokoyama W.M., Ugolini S. Innate or adaptive immunity? The example of Natural Killer cells. Science, 2011, 331: 44-49.

Narni-Mancinelli E., Vivier E. NK genesis: a trick of the TRAIL. Immunity, 2012, 36: 1-3.

Vivier E., Ugolini S., Blaise D., Chabannon C., Brossay L. Targeting Natural killer cells and natural killer T cells in cancer. Nature Reviews Immunol. 2012, 12: 239-252.

Jaeger B.N., Vivier E. When Natural Killer cells overcome their lack of education. J. Clin. Invest. 2012, 122:3053.

Spits H., Artis D., Colonna M., Diefenbach A., Di Santo J.P., Eberl G., Koyasu S., Locksley R.M. McKenzie A.N.J., Mebius R.E., Powrie F., Vivier E. Innate Lymphoid Cells: a proposal for a uniform nomenclature. Nature Reviews Immunol. 2013. 13:145-149.

Kerdiles Y., Ugolini S., Vivier E. T cell regulation of Natural Killer cells. J. Exp. Med. 2013, 210: 1065-1068.

Pradeu P., Jaeger S. Vivier E. The Speed of Change: Towards a Discontinuity Theory of Immunity. Nature Reviews Immunol. 2013, 13: 764-769.

Vivier E., Ugolini S., Nunès J.A. ADAPted cytokine secretion in Natural Killer cells. Nature Immunology, 2013, 14:1108-1110.

Daëron M, Vivier E. Coincidence detection of antibodies and interferon for sensing microbial context. Nature Immunology, 2014, 15: 316-317.

Sun J.C., Ugolini S., Vivier E. Immunological Memory within the Innate Immune System. EMBO J., 2014; 33(12):1295-303.

Narni-Mancinelli N., Vivier E. Perforin, granulysin and granzymes: an anti-bacterial tritherapy

provided by killer lymphocytes. Cell, 2014;157(6):1251-2.

Crouse J, Bedenikovic G, Wiesel M, Ibberson M, Xenarios I, Von Laer D, Kalinke U, Vivier E, Jonjic S, Oxenius A. Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1. Immunity. 2014;40(6):961-73.

Celis-Gutierrez J, Boyron M, Walzer T, Pandolfi PP, Jonji? S, Olive D, Dalod M, Vivier E, Nunès JA. Dok1 and Dok2 proteins regulate natural killer cell development and function. EMBO J. 2014;33(17):1928-40.

Marçais A, Cherfils-Vicini J, Viant C, Degouve S, Viel S, Fenis A, Rabilloud J, Mayol K, Tavares A, Bienvenu J, Gangloff YG, Gilson E, Vivier E, Walzer T.  The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells.Nat Immunol. 2014;15(8):749-57.

Viant C, Fenis A, Chicanne G, Payrastre B, Ugolini S, Vivier E. SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells. Nat Commun. 2014;5:5108.